Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract

Table 1 Sequences of primers and probes

Target gene(amplicon size)		Sequence (5'-3')
HAI-1	Upstream primer	TGA GGA AGA GCA GCA GTG CC
(151 bp)	Downstream primer	GGC TAC CAC CAC CAC AAT GC
	Probe	FAM -CCA GCA CAG GCT CTG TGG AGA
		TGG C -TAMRA
SNC19/	Upstream primer	GGG ACA CAC CCA GTA TGG AGG
matriptase
(168 bp)	Downstream primer	CCG GAA TCA CCC TGG CAG GA
	Probe	FAM -TCC TGC AAA AGG GTG AGA TCC
		GCG -TAMRA
GAPDH	Upstream primer	CTT AGC ACC CCT GGC CAA G
(151 bp)	Downstream primer	GAT GTT CTG GAG AGC CCC G
	Probe	FAM -CAT GCC ATC ACT GCC ACC CAG
		AAG A -TAMRA

Table 2 Expression of HAI-1 and SNC19/matriptase in normal and malignant tissues of gastrointestinal tract [M(QR)]

	Gastric tissues			Colorectal tissues
	HAI-1	SNC19	HAI-1:SNC19	HAI-1	SNC19	HAI-1:SNC19
Normal tissues	0.012（0.021）	0.010（0.014）	1.420（1.662）	0.014（0.022）	0.010（0.014）	0.971（1.415）
Malignant tissues	0.005（0.013）	0.004（0.005）	1.365（1.820）	0.009（0.007）	0.005（0.005）	1.520（1.215）
Z	-3.28	-4.651	-0.121	-3.1	-2.731	-0.999
P	0.001	0	0.904	0.002	0.006	0.318

Table 3 Correlation between HAI-1 and SNC19/matriptase expression and clinicopathology in gastric cancer tissues [M(QR)]

	Patients	HAI-1	SNC19	HAI-1:SNC19
Age (yr)
<40 yr	3	0.005 (0.011)	0.003 (0.002)	1.415 (1.416)
40-60 yr	17	0.005 (0.016)	0.005 (0.006)	1.680 (2.022)
>60 yr	20	0.005 (0.001)	0.003 (0.003)	0.882 (0.144)
Gender
Men	28	0.005 (0.013)	0.004 (0.004)	1.220 (1.631)
Women	12	0.005 (0.020)	0.003 (0.005)	1.680 (1.571)
Location
Cardia	7	0.005 (0.004)	0.003 (0.002)	1.430 (0.210)
Body	7	0.007 (0.023)	0.004 (0.005)	2.620 (2.846)
Pylorus	17	0.005 (0.015)	0.005 (0.005)	1.080 (1.631)
Unkown	9	0.005 (0.110)	0.003 (0.004)	1.220 (1.219)
Tumor histology
adenocarcinoma	18	0.005 (0.008)	0.004 (0.004)	1.365 (1.442)
Mucoid carcinoma	7	0.005 (0.021)	0.003 (0.008)	1.740 (1.626)
Poorly differentiated carcinoma	11	0.003 (0.016)	0.003 (0.004)	0.882 (2.377)
Unkown	4	0.005 (0.114)	0.005 (0.004)	1.555 (1.386)
N factor
N0	12	0.017 (0.032) a	0.004 (0.005)	2.280 (3.148) e
N1/N2	28	0.004 (0.005)	0.004 (0.005)	1.080 (1.489)
UICC stage
I/II	10	0.017 (0.020) c	0.004 (0.005)	2.280 (2.718) g
III/IV	30	0.004 (0.007)	0.003 (0.004)	1.245 (1.541)
Histological grade
Well	3	0.011 (0.008)	0.003 (0.002）	2.870 (1.753)
Moderately	15	0.005 (0.004)	0.004 (0.004）	1.400 (1.121)
Poorly	22	0.004 (0.017)	0.003 (0.007）	1.150 (0.470)

^aP<0.05,

^cP <0.05 vs lymph node-positive group (N1/N2); ^eP <0.05, ^gP<0.05 vs stage III/IV group.

Table 4 Correlation between HAI-1 and SNC19/matriptase expression and clinicopathology in colorectal cancer tissues [M(Q_R)]

	Patients	HAI-1	SNC19	HAI-1:SNC19
Age yr
<40 yr	3	0.004 (0.003)	0.005 (0.002)	0.778 (0.349)
40-60 yr	10	0.007 (0.102)	0.003 (0.003)	0.798 (1.096)
>60 yr	23	0.009 (0.104)	0.005 (0.005)	0.677 (0.459)
Unkown	1
Gender
Men	13	0.005 (0.109)	0.005 (0.006)	0.944 (0.728)
Women	24	0.009 (0.100)	0.005 (0.004)	0.667 (0.592)
Location
Cecum/ascending colon	9	0.009 (0.101)	0.005 (0.006)	0.660 (0.482)
Transverse colon	2	0.003 (0.003)	0.002 (0.002)	0.862 (0.377)
Descending/sigmoid colon	6	0.010 (0.004)	0.006 (0.002)	0.663 (0.715)
Rectum	19	0.005 (0.009)	0.004 (0.005)	0.778 (1.158)
Unknown	1
Tumor histology
Adenocarcinoma	32	0.005 (0.009)	0.004 (0.005)	0.734 (0.788)
Mucoid carcinoma	4	0.009 (0.012)	0.005 (0.004)	0.511 (0.194)
Poorly differentiated carcinoma	1
N factor
N0	18	0.010（0.015）	0.005（0.009）	1.470（0.699）
N1/N2	19	0.007（0.005）	0.005（0.004）	1.480（0.980）
Dukes’ stage
A	7	0.011（0.015）	0.004（0.008）	1.790（3.860）
B	10	0.010（0.016）	0.006（0.015）	1.290（1.243 ）
C/D	20	0.006（0.006）	0.005（0.005）	1.385（0.955）
Histological grade
Well	8	0.005（0.010）	0.006（0.024）	0.891（1.482）
Moderately	24	0.009（0.009）	0.004（0.005）	1.485（1.250 ）
Poorly	5	0.009（0.012）	0.005（0.005）	1.790（1.000）